NSTEMI - Non-ST Segment Elevation MI Clinical Trial
Official title:
Implementing Precision Medicine Approaches to Guide Anti-platelet Selection Following Percutaneous Coronary Intervention (PCI)
The study aims to determine the feasibility and clinical utility of incorporating precision medicine approaches, incorporating both cytochrome P450 2C19 (CYP2C19) genotyping and platelet reactivity phenotyping, with standard of care for patients with acute coronary syndromes (ACS), post PCI.
Study Population: Adult patients will be eligible for inclusion if they provide informed consent and have no contraindications for 12-months of dual antiplatelet therapy (DAPT). Baseline Evaluation: Overview of clinical protocol: Patients with successful PCI will receive a genotype guided recommendation, upon discharge, based on CYP2C19 genotype. Patients who are determined to have CYP2C19 poor metabolizer (PM) or intermediate metabolizer (IM) status will be recommended to receive 12-months of prasugrel. Patients who are determined to have CYP2C19 normal metabolizer (NM), rapid metabolizer (RM), or ultra-rapid metabolizer (UM) phenotype will be recommended to receive a de-escalation treatment, guided by on-treatment platelet reactivity phenotype at 14 days, post discharge. 30-day, 6-month, and 12-month Follow-up: Patients will be contacted by phone or visited during one of their regularly scheduled appointments, at 14 days, 30 days, 6 months , and 12 months, to complete "Follow-up Case Report Forms" to collect outcomes data. The 12-month follow up communication with enrolled patients will end their participation in the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04951856 -
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
|
Phase 4 | |
| Completed |
NCT03103620 -
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
|
||
| Completed |
NCT04648306 -
Restore EF Observational Study
|
||
| Recruiting |
NCT06095557 -
MCG Discovery Study in Emergency Departments
|
N/A | |
| Not yet recruiting |
NCT04403048 -
Drug Coated Balloon for Side Branch Treatment vs. Conventional Approach in True Bifurcation Coronary Disease: PRO-DAVID
|
N/A | |
| Completed |
NCT03489603 -
Clinical and Economic Outcomes of High Sensitivity Troponin for no ST Elevation Myocardial Infarction in Patients With Chest Pain in Emergency Departments in Italy-An Observational Study
|
||
| Recruiting |
NCT04140019 -
Early Cardiac Magnetic Resonance Imaging in Suspected Non-ST-Elevation Myocardial Infarction
|
||
| Completed |
NCT04289012 -
HELicobacter Pylori Screening in Patients With Acute Myocardial Infarction Pilot Study
|
N/A | |
| Active, not recruiting |
NCT03052036 -
The British Heart Foundation SENIOR-RITA Trial
|
N/A | |
| Completed |
NCT02983123 -
One-hour Troponin in a Low-prevalence Population of Acute Coronary Syndrome
|
||
| Completed |
NCT03943966 -
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer
|
N/A | |
| Completed |
NCT03677180 -
National Cardiogenic Shock Initiative
|
||
| Completed |
NCT03507777 -
ILUMIEN IV: OPTIMAL PCI
|
N/A | |
| Recruiting |
NCT03863327 -
EKG Criteria and Identification of Acute Coronary Occlusion
|
||
| Completed |
NCT03461484 -
e-BioMatrix 6 Month DAPT France
|
||
| Recruiting |
NCT03089450 -
To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent
|
N/A | |
| Recruiting |
NCT03562572 -
FFR Driven Complete Revascularization Versus Usual Care in NSTEMI Patients and Multivessel Disease
|
N/A | |
| Completed |
NCT03822377 -
Ticagrelor Administered as Standard Tablet or Orodispersible Formulation
|
Phase 3 | |
| Recruiting |
NCT04002739 -
PRedictOrs, PHEnotypes and Timing of Obstructive Sleep Apnea in Acute Coronary Syndrome
|
N/A | |
| Completed |
NCT03111862 -
Safety of Accelerated Rule-out Protocols in Patients Admitted With Chest Pain to a Crowded Chest Pain Unit (CPU)
|